2. Search Result
Search Result
Results for "

colchicine site tubulin

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155362
    Tubulin polymerization-IN-56

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-56 (compound 8l), an indazole derivative, is a potent tubulin polymerization inhibitor through interacting with the colchicine site, resulting in cell cycle arrest and cellular apoptosis. polymerization-IN-56 reduces cell migration and leads to more potent inhibition of tumor growth in vivo .
    Tubulin polymerization-IN-56
  • HY-152156
    Tubulin inhibitor 11

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin inhibitor 11 is a potent and orally active tubulin inhibitor. Tubulin inhibitor 11 targets the Colchicine binding site on tubulin, inhibits tubulin polymerization, promotes mitotic blockade and apoptosis .
    Tubulin inhibitor 11
  • HY-157543
    Tubulin polymerization-IN-59

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-59 ((R)-9k) is a potent inhibitor of colchicine binding site inhibitor (CBSI). Tubulin polymerization-IN-59 inhibits tubulin polymerization .
    Tubulin polymerization-IN-59
  • HY-155139
    Tubulin polymerization-IN-45

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-45, a tubulin-targeting agent, is a tubulin polymerization inhibitor. Tubulin polymerization-IN-45 binds to the colchicine site of tubulin. Tubulin polymerization-IN-45 induces apoptotic cell death in hepatocellular cancer (HCC) cells .
    Tubulin polymerization-IN-45
  • HY-156737
    Tubulin polymerization-IN-49

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-49 (compound 12d) is a potent tubulin polymerization inhibitor. Tubulin polymerization-IN-49 bound to colchicine site on tubulin and inhibited tubulin polymerization. Tubulin polymerization-IN-49 induces cell cycle arrest at G2/M phase and apoptosis. Tubulin polymerization-IN-49 has anticancer active and prevents tumor generation, inhibits tumor proliferation and angiogenesis .
    Tubulin polymerization-IN-49
  • HY-175698
    Ferroptosis inducer-9

    		Ferroptosis Microtubule/Tubulin COX Glutathione Peroxidase Cancer
    Ferroptosis inducer-9 is a ferroptosis inducer and colchicine site tubulin polymerization inhibitor. Ferroptosis inducer-9 inhibits MCF-7 cell growth with an IC50 of 14 nM and inhibits [ 3H]colchicine binding. Ferroptosis inducer-9 reduces expression of GPX4 and FTH, increases COX2 and ACSL4, lowers GSH, NADP+, and NADPH levels, increases LPO, MDA, and Fe(II) levels, and decreases SOD concentrations. Ferroptosis inducer-9 demonstrates significant anti-tumor efficacy in HCT116 CRC xenograft model. Ferroptosis inducer-9 can be used for the study of triple negative breast cancer (TNBC) and colorectal cancer (CRC) .
    Ferroptosis inducer-9
  • HY-151398
    Tubulin polymerization-IN-37

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-37 is a tubulin polymerization inhibitor (IC50: 2.3 μΜ). Tubulin polymerization-IN-37 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-37 can be used in the research of cancers, such as lymphomas .
    Tubulin polymerization-IN-37
  • HY-151397
    Tubulin polymerization-IN-36

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-36 is a tubulin polymerization inhibitor (IC50: 2.8 μΜ). Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-36 can be used in the research of cancers, such as lymphomas .
    Tubulin polymerization-IN-36
  • HY-170864
    BKS3031A

    		Microtubule/Tubulin Neurological Disease Cancer
    BKS3031A is the inhibitor for αβ-tubulin that binds to the colchicine binding site, and inhibits the microtubule assembly dynamics .
    BKS3031A
  • HY-152143
    Tubulin polymerization-IN-41

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-41 is a potent tubulin polymerization inhibitor with the IC50 of 2.61 μM. Tubulin polymerization-IN-41 targets the Colchicine-binding site of tubulin. Tubulin polymerization-IN-41 has anticancer effects .
    Tubulin polymerization-IN-41
  • HY-151982
    Tubulin polymerization-IN-39

    		Microtubule/Tubulin Cardiovascular Disease Cancer
    Tubulin polymerization-IN-39 is a tubulin polymerization inhibitor (IC50: 4.9 μM). Tubulin polymerization-IN-39 occupies the colchicine-binding site. Tubulin polymerization-IN-39 inhibits cancer cell proliferation .
    Tubulin polymerization-IN-39
  • HY-163270
    PM534

    		Microtubule/Tubulin Cancer
    PM534, tubulin targeting agent, inhibits tubulin assembly with IC50 values of 0.8-3.2 nM. PM534 binds to the colchicine site of tubulin, which has high antitumor activity .
    PM534
  • HY-16372
    CP 461

    OSI-461

    		 Apoptosis Microtubule/Tubulin Cancer
    CP-461 (OSI-461) is a selective apoptotic antineoplastic drug (SAAND) by engaging tubulin on colchicine site
    CP 461
  • HY-147888
    Tubulin inhibitor 29

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor with an IC50 value of 1.2 µM. Tubulin inhibitor 29 shows antiproliferative effects with an IC50 value of 7.5 µM for MCF-7 cells. Tubulin inhibitor 29 inhibits tubulin assembly and bounds in the colchicine site .
    Tubulin inhibitor 29
  • HY-163356
    Tubulin polymerization-IN-60

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-60 (BF3) is a tubulin polymerization inhibitor with anticancer activity. Tubulin polymerization-IN-60 (BF3) belongs to the colchicine binding site inhibitors (CBSIs) and disturbs cell cycle progression leading to G2/M arrest and apoptosis .
    Tubulin polymerization-IN-60
  • HY-106008
    Avanbulin

    BAL27862

    		 Microtubule/Tubulin Cancer
    Avanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.4 μM. Avanbulin binds to tubulin with an apparent Kd value of 244 nM. Avanbulin can be used for the research of cancer and cell division .
    Avanbulin
  • HY-170563
    Tubulin polymerization-IN-72

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-72 (Compound 4a4) is an anticancer agent that acts as a tubulin polymerization inhibitor. It inhibits tubulin polymerization by binding to the colchicine site, leading to cancer cell arrest in the G2/M phase and inducing their apoptosis (Apoptosis). Tubulin polymerization-IN-72 has an IC50 of 0.4-2.7 nM against cancer cells.
    Tubulin polymerization-IN-72
  • HY-14444
    Plinabulin
    2 Publications Verification

    NPI-2358

    		 Microtubule/Tubulin Cancer
    Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells . Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells .
    Plinabulin
  • HY-149363
    Tubulin polymerization-IN-43

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-43 (compound 15h) is a tubulin polymerization inhibitor. Tubulin polymerization-IN-43 disrupts cellular microtubule networks by targeting the Colchicine (HY-16569) site, and promots cell cycle arrest of leukemia cells at G2/M phase and cell apoptosis, as well as inhibiting angiogenesis .
    Tubulin polymerization-IN-43
  • HY-106825
    Clanfenur

    		Microtubule/Tubulin Cancer
    Clanfenur is a substituted benzoylphenylurea, an analogue of the pesticide fenfluramide, with potential antineoplastic activity. Clanfenur can bind to the colchicine-binding site on β-tubulin, inhibit microtubule polymerization, and thus prevent tumor cell replication .
    Clanfenur
  • HY-121993
    Combretastatin A-1

    		Wnt Microtubule/Tubulin Cancer
    Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 exhibits anti-tumor and anti-vascular effects .
    Combretastatin A-1
  • HY-149020
    Tubulin polymerization-IN-26

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-26 (compound 12h) can inhibit the polymerization of microtubulin by binding to the colchicine binding site of microtubulin with an IC50 value of 4.64 μM. Tubulin polymerization-IN-26 can induce apoptosis and inhibit cell metastasis or migration, and can be used as a potential compound for lung cancer research .
    Tubulin polymerization-IN-26
  • HY-118748
    Suprafenacine

    SRF

    		 Microtubule/Tubulin Cancer
    Suprafenacine is a cell permeable, tubulin-destabilizing molecule which bind microtubules at the colchicine-binding site and inhibit polymerization. Suprafenacine can induce G2/M cell cycle arrest and apoptosis, and can be used for cancer research .
    Suprafenacine
  • HY-168565
    Tubulin polymerization-IN-70

    		Apoptosis Microtubule/Tubulin Reactive Oxygen Species (ROS) Cancer
    Tubulin polymerization-IN-70 (compound Q19) is a potent tubulin polymerization inhibitor. Tubulin polymerization-IN-70 shows antiproliferative activity. Tubulin polymerization-IN-70 target the colchicine binding site of tubulin and inhibited tubulin polymerization. Tubulin polymerization-IN-70 induces apoptosis and cell cycle arrest at G2/M phase. Tubulin polymerization-IN-70 induces mitochondrial membrane potential decrease and increases the levels of reactive oxygen species (ROS). Tubulin polymerization-IN-70 shows antiangiogenic and anticancer activity .
    Tubulin polymerization-IN-70
  • HY-121524
    DJ101

    		Microtubule/Tubulin Cancer
    DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research .
    DJ101
  • HY-124083
    MPT0B214

    		Microtubule/Tubulin Apoptosis Caspase Mitochondrial Metabolism Cancer
    MPT0B214 is a microtubule inhibitor that strongly binds to the colchicine binding site of tubulin, preventing tubulin polymerization. MPT0B214 induces apoptosis through a mitochondrial/caspase 9 dependent pathway and shows cytotoxicity across various human tumor cell lines. MPT0B214 can be used for cancer research .
    MPT0B214
  • HY-175512
    Tubulin-IN-53

    		Microtubule/Tubulin Apoptosis Reactive Oxygen Species (ROS) Cancer
    Tubulin-IN-53 is a potent Tubulin inhibitor with an IC50 of 6.06 μM. Tubulin-IN-53 inhibits the polymerization of tubulin by targeting the colchicine binding site of tubulin and destroys the microtubule network. Tubulin-IN-53 induces MCF-7 cell cycle arrest in the G2/M phase and apoptosis, and inhibits cell migration accompanied by the decrease of mitochondrial membrane potential and increase the accumulation of ROS. Tubulin-IN-53 destroys the angiogenesis of human umbilical vein endothelial cells.Tubulin-IN-53 can used for the study of cancers such as breast cancer and lung cancer .
    Tubulin-IN-53
  • HY-162227
    Antitumor agent-138

    		Microtubule/Tubulin Apoptosis Cancer
    Antitumor agent-138 (compound 5b) is an inhibitor against tubulin polymerization at tubulin colchicine-binding sites, with IC50 of 1.87 μM. Antitumor agent-138 arrests the cell cycle at G2/M phase and induces an apoptosis in MCF-7 cells. Antitumor agent-138 inhibits cells migration and angiogenesis .
    Antitumor agent-138
  • HY-147947
    Tubulin polymerization-IN-30

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-30 (compound 6e) is a potent Tubulin polymerization inhibitor. Tubulin polymerization-IN-30 is a colchicine binding site inhibitor. Tubulin polymerization-IN-30 can disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. Tubulin polymerization-IN-30 exhibits the high potency against the cancer cell lines including SGC-7901, A549 and HeLa, with IC50 values of 2.16, 2.21, and 0.403 μM .
    Tubulin polymerization-IN-30
  • HY-163692
    Tubulin polymerization-IN-64

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-64 (Compound 8a) is an inhibitor for tubulin polymerization by occupying the colchicine binding site of tubulin, with IC50 of 6.9 μM. Tubulin polymerization-IN-64 inhibits proliferations of cancer cells A549, HeLa, HCT116 and HT-29, with IC50s of 2.42, 10.33, 6.28, 5.33 μM, respectively. Tubulin polymerization-IN-64 arrests cell cycle at G2/M phase, induces apoptosis in A549 .
    Tubulin polymerization-IN-64
  • HY-119427
    Anti-melanoma agent 3

    		Microtubule/Tubulin Cancer
    Anti-melanoma agent 3 (compound 5cb) is a 2-aryl-4-benzoyl-imidazole (ABI) derivative and an inhibitor of melanoma xenogeneic tumors. Anti-melanoma agent 3 exerts anticancer activity by interacting with the colchicine binding site to inhibit tubulin polymerization .
    Anti-melanoma agent 3
  • HY-161324
    Tubulin degrader 1

    		Microtubule/Tubulin Cancer
    Tubulin degrader 1 (Compound 5i) is a BML284 (HY-19987) derivative that is an orally active colchicine-site noncovalent tubulin degradation agent with IC50 values ranging from 0.02 to 0.05 μM against the five tumor cell lines (Hela, HCT116, MCF-7, K562 and Molm-13). Tubulin degrader 1 has antiproliferative activity that effectively suppressed tumor growth .
    Tubulin degrader 1
  • HY-162319
    Tubulin/HDAC-IN-4

    		Apoptosis HDAC Microtubule/Tubulin Reactive Oxygen Species (ROS) Cancer
    Tubulin/HDAC-IN-4 (compound 9n) is a dual Tubulin and HDAC inhibitor with IC50 values of 0.73, 0.43, 0.62, 2.34 µM for HDAC1, HDAC2, HDAC6, HDAC7, respectively. Tubulin/HDAC-IN-4 inhibits the tubulin polymerization by targeting the colchicine binding site. Tubulin/HDAC-IN-4 induces apoptosis and cell cycle arrest at G2/M phase. Tubulin/HDAC-IN-4 induces a significant elevation of intracellular ROS levels. Tubulin/HDAC-IN-4 shows anti-angiogenesis activity and anticancer activity .
    Tubulin/HDAC-IN-4
  • HY-16146
    Combretastatin A-1 phosphate tetrasodium

    OXi-4503 tetrasodium

    		 Wnt Microtubule/Tubulin Cancer
    Combretastatin A-1 phosphate (OXi-4503) tetrasodium, a proagent of Combretastatin A-1, is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 phosphate tetrasodium inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 phosphate tetrasodium exhibits anti-tumor and anti-vascular effects .
    Combretastatin A-1 phosphate tetrasodium
  • HY-162089
    MY-1442

    		Microtubule/Tubulin Apoptosis Cancer
    MY-1442 (I-3) is a microtubulin polymerization inhibitor. MY-875 inhibits tubulin polymerization by targeting colchicine binding sites. MY-1442 has anticancer activity. MY-1442 can induce apoptosis of MGC-803 cells and inhibit cell migration .
    MY-1442
  • HY-163523
    PYRIB-SO 2

    		Microtubule/Tubulin Cancer
    PYRIB-SO 2 is a potent antimitotic agent. PYRIB-SO 2 shows antiproliferative activity and induces cell cycle arrest at G2/M phase. PYRIB-SO 2 reduces and disruptes microtubule structures. PYRIB-SO 2 binds to the colchicine-binding site (C-BS) of α, β-tubulin .
    PYRIB-SO 2
  • HY-149414
    MY-673

    		Microtubule/Tubulin Apoptosis ERK TGF-beta/Smad Cancer
    MY-673 is a colchicine binding site inhibitor (CBSI), that inhibits tubulin polymerization. MY-673 inhibits the ERK signaling pathway, which in turn affects SMAD4 protein expression levels in the TGF-β/SMAD pathway. MY-673 inhibited cell proliferation, migration and induced apoptosis in vivo and in vitro .
    MY-673
  • HY-121993R
    Combretastatin A-1 (Standard)

    		Wnt Microtubule/Tubulin Cancer
    Combretastatin A-1 (Standard) is the analytical standard of Combretastatin A-1. This product is intended for research and analytical applications. Combretastatin A-1 is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. Combretastatin A-1 inhibits the Wnt/β-catenin pathway through tubulin depolymerization mediated AKT deactivation. Combretastatin A-1 exhibits anti-tumor and anti-vascular effects .
    Combretastatin A-1 (Standard)
  • HY-176171
    Tubulin polymerization-IN-79

    		Microtubule/Tubulin Hippo (MST) YAP Apoptosis Cancer
    Tubulin polymerization-IN-79 (Compound C20) is a tubulin polymerization inhibitor. Tubulin polymerization-IN-79 shows potent antiproliferative activity against esophageal cancer cells (e.g., KYSE450, IC50=0.36 μM; EC-109, IC50=0.63 μM). Tubulin polymerization-IN-79 occupies the colchicine binding site to disrupt microtubule network integrity, activating the Hippo signaling pathway, downregulating the oncogenic protein YAP expression, and inducing G2/M phase arrest and apoptosis in esophageal cancer cells. Tubulin polymerization-IN-79 is promising for research of esophageal cancers .
    Tubulin polymerization-IN-79
  • HY-161863
    Tubulin polymerization-IN-67

    		Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis Cancer
    Tubulin polymerization-IN-67 (Compound 5h) is an inhibitor for tubulin polymerization on colchicine binding site with an IC50 of 2.92 μM. Tubulin polymerization-IN-67 inhibits the proliferation of cancer cells HT29, A549, U2OS, MG-63 and HeLa with IC50s of 0.12-4.13 μM. Tubulin polymerization-IN-67 arrests the cell cycle at G2/M phase, induces apoptosis in cell U2OS, inhibits the cell migration of A549. Tubulin polymerization-IN-67 reduces the mitochondrial membrane potential (MMP) and increase intracellular ROS, inhibits the angiogenesis in HUVECs. Tubulin polymerization-IN-67 exhibits antitumor efficacy in mice
    Tubulin polymerization-IN-67
  • HY-170924
    Tubulin polymerization-IN-76

    		Microtubule/Tubulin Apoptosis Mitosis Cancer
    Tubulin polymerization-IN-76 (compound 20b) is a potent and orally active Tubulin polymerization inhibitor. Tubulin polymerization-IN-76 inhibits Tubulin polymerization with an IC50 of 2.505 μM by acting on the colchicine binding site, thereby disrupting intracellular Microtubule networks and interfering with cell mitosis. Tubulin polymerization-IN-76 demonstrates exceptional efficacy against MGC-803 and HGC-27 cells with IC50s of 1.61 and 1.82 nM, respectively. Tubulin polymerization-IN-76 effectively inhibits the colony formation and cell migration activities, and induces G2/M phase cycle arrest and Apoptosis in MGC-803 and HGC-27 cells.Tubulin polymerization-IN-76 shows a broad-spectrum antiproliferative activity .
    Tubulin polymerization-IN-76
  • HY-159921
    Tubulin Polymerization-IN-1 prodrug

    		Microtubule/Tubulin Cancer
    Tubulin Polymerization-IN-1 prodrug (Compound 2b) is a palladium (Pd)-mediated tubulin polymerization inhibitor prodrug. Developed based on colchicine binding site inhibitors (CBSIs), it reduces toxicity and enhances targeted release properties. Compared to the parent compound, Tubulin Polymerization-IN-1 prodrug exhibited 68.3-fold lower cytotoxicity, which can be restored in situ in the presence of Pd resin. Mechanistic studies showed that its anticancer activity is consistent with CBSIs. In vivo, Tubulin Polymerization-IN-1 prodrug significantly inhibited tumor growth (63.2%) when activated by Pd resin. It holds promise for research in the field of anticancer therapy .
    Tubulin Polymerization-IN-1 prodrug
  • HY-13270
    ABT-751

    E7010

    		 Microtubule/Tubulin Autophagy Apoptosis Cancer
    ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer .
    ABT-751
  • HY-149374
    Tubulin inhibitor 36

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 36 (Compound 10) is a novel and potent tubulin inhibitor and inhibits the polymerization of microtubular protein then induces apoptosis with an IC50 value of 1.5±0.1 μM. Tubulin inhibitor 36 (Compound 10) has significant anti-mitotic effect and exhibits activities against glioblastoma cells. Tubulin inhibitor 36 (Compound 10) has anti-tumor effects and can be used for glioblastoma multiforme (GBM) research .
    Tubulin inhibitor 36
  • HY-13270A
    ABT-751 hydrochloride

    E7010 hydrochloride

    		 Microtubule/Tubulin Autophagy Apoptosis Cancer
    ABT-751 (E7010) hydrochloride is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 (E7010) hydrochloride induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 (E7010) hydrochloride showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer .
    ABT-751 hydrochloride
  • HY-176283
    Tubulin/LSD1-IN-1

    		Microtubule/Tubulin Histone Demethylase Apoptosis Wee1 Bcl-2 Family Caspase Cancer
    Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and LSD1 (IC50 = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells .
    Tubulin/LSD1-IN-1
  • HY-13270R
    ABT-751 (Standard)

    		Microtubule/Tubulin Autophagy Apoptosis Cancer
    ABT-751 (Standard) is the analytical standard of ABT-751. This product is intended for research and analytical applications. ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer .
    ABT-751 (Standard)
  • HY-Z8644
    N-Deacetyl-N-formylcolchicine

    N-Formyl-N-deacetylcolchicine

    		 Microtubule/Tubulin Apoptosis Cancer
    N-Deacetyl-N-formylcolchicine (N-Formyl-N-deacetylcolchicine, Compound 11) is a selective inhibitor targeting the colchicine-binding site of tubulin. N-Deacetyl-N-formylcolchicine shows antiproliferative activity against various cancer cell lines with IC50 values of 32.61-100.28 nM. N-Deacetyl-N-formylcolchicine inhibits microtubule polymerization to block cell division, induces cancer cell apoptosis and suppresses migration. N-Deacetyl-N-formylcolchicine is promising for research of cancers such as lung cancer and various solid tumors .
    N-Deacetyl-N-formylcolchicine
  • HY-148265
    Antiproliferative agent-14

    		Microtubule/Tubulin Cancer
    Antiproliferative agent-14 (compound 3b) a potent tubulin polymerization inhibitor, with an IC50 of 3.41 μM. Antiproliferative agent-14 has excellent antiproliferative activity. Antiproliferative agent-14 possess the ability to arrest cells at G2/M phases of the cell cycle .
    Antiproliferative agent-14
  • HY-173182
    Antitumor agent-200

    		Microtubule/Tubulin P-glycoprotein Cancer
    Antitumor agent-200 (Compound 2g) is a microtubule synthesis inhibitor. By binding to the colchicine site of tubulin, it causes G2/M cell cycle arrest and generates reactive oxygen species (ROS). Antitumor agent-200 exhibits significant inhibitory activity against MCF7/ADR and KBV200 cell lines with overexpression of P-glycoprotein (P-gp), with drug resistance indices (DRI) of 0.83 and 0.58 respectively. In the MCF-7 xenograft model, Antitumor agent-200 (25 mg/kg, intraperitoneal injection) can achieve a tumor growth inhibition rate of 57.2%. Antitumor agent-200 can be used in the research of the anti-cancer field .
    Antitumor agent-200

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: